Evofem Biosciences Files Q1 2025 10-Q
Ticker: EVFM · Form: 10-Q · Filed: May 15, 2025 · CIK: 1618835
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
Related Tickers: EVFM
TL;DR
EVFM Q1 2025 10-Q filed. Financials and operations updated.
AI Summary
Evofem Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 2025. Key financial data and operational updates are presented, reflecting the company's performance and strategic direction.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Evofem Biosciences, Inc. for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Evofem Biosciences faces inherent risks related to drug development, regulatory approvals, market competition, and financial performance.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date
- Neothetics, Inc. (company) — Former company name
- 20140905 (date) — Date of name change
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250515.
What was Evofem Biosciences, Inc. previously known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc., with a name change occurring on 20140905.
What is the Standard Industrial Classification code for Evofem Biosciences, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Evofem Biosciences, Inc. headquartered?
The company's business address is 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA 92130.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Evofem Biosciences, Inc. (EVFM).